| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Statistical | 10 | 2011 | 448 | 1.040 |
Why?
|
| Brain Ischemia | 12 | 2014 | 665 | 0.820 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2016 | 931 | 0.820 |
Why?
|
| Clinical Trials as Topic | 9 | 2009 | 848 | 0.640 |
Why?
|
| Longitudinal Studies | 9 | 2011 | 1054 | 0.600 |
Why?
|
| Research Design | 13 | 2014 | 729 | 0.590 |
Why?
|
| Hypertension | 8 | 2011 | 1535 | 0.520 |
Why?
|
| Diabetes Complications | 2 | 2016 | 249 | 0.510 |
Why?
|
| Lipids | 1 | 2016 | 298 | 0.500 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 343 | 0.470 |
Why?
|
| Data Interpretation, Statistical | 9 | 2014 | 329 | 0.450 |
Why?
|
| Cerebrovascular Disorders | 6 | 1999 | 182 | 0.440 |
Why?
|
| Stroke | 7 | 2014 | 2163 | 0.420 |
Why?
|
| Poisson Distribution | 2 | 2011 | 85 | 0.410 |
Why?
|
| Diabetes Mellitus | 2 | 2016 | 694 | 0.410 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2011 | 20 | 0.390 |
Why?
|
| C-Reactive Protein | 4 | 2008 | 180 | 0.390 |
Why?
|
| Dermatan Sulfate | 8 | 2004 | 12 | 0.380 |
Why?
|
| Heparitin Sulfate | 8 | 2004 | 20 | 0.380 |
Why?
|
| Chondroitin Sulfates | 8 | 2004 | 44 | 0.370 |
Why?
|
| Sleep Wake Disorders | 1 | 2011 | 94 | 0.370 |
Why?
|
| Candy | 1 | 2010 | 3 | 0.360 |
Why?
|
| Cacao | 1 | 2010 | 11 | 0.360 |
Why?
|
| Humans | 93 | 2016 | 68618 | 0.350 |
Why?
|
| Treatment Outcome | 20 | 2016 | 7029 | 0.350 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2014 | 296 | 0.340 |
Why?
|
| Magnesium | 2 | 2011 | 110 | 0.340 |
Why?
|
| Primary Prevention | 1 | 2010 | 115 | 0.330 |
Why?
|
| Veterans | 10 | 2007 | 904 | 0.330 |
Why?
|
| Ankylosis | 1 | 2008 | 5 | 0.320 |
Why?
|
| Abdominal Fat | 1 | 2008 | 8 | 0.320 |
Why?
|
| Stroke Volume | 1 | 2011 | 586 | 0.320 |
Why?
|
| Temporomandibular Joint | 1 | 2008 | 18 | 0.320 |
Why?
|
| Temporomandibular Joint Disorders | 1 | 2008 | 20 | 0.320 |
Why?
|
| Statistics as Topic | 6 | 2006 | 219 | 0.320 |
Why?
|
| Arthroplasty, Replacement | 1 | 2008 | 48 | 0.300 |
Why?
|
| Kidney Transplantation | 4 | 2011 | 839 | 0.300 |
Why?
|
| Discriminant Analysis | 3 | 1997 | 36 | 0.290 |
Why?
|
| Fibrinolytic Agents | 8 | 2014 | 377 | 0.280 |
Why?
|
| Gulf War | 4 | 2007 | 22 | 0.280 |
Why?
|
| Regression Analysis | 9 | 2011 | 737 | 0.270 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2005 | 58 | 0.260 |
Why?
|
| Benzhydryl Compounds | 1 | 2006 | 62 | 0.260 |
Why?
|
| Guideline Adherence | 3 | 2003 | 287 | 0.260 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 84 | 0.250 |
Why?
|
| Female | 49 | 2016 | 38074 | 0.250 |
Why?
|
| Computer Simulation | 9 | 2008 | 706 | 0.240 |
Why?
|
| Male | 46 | 2016 | 37321 | 0.240 |
Why?
|
| Physicians | 2 | 2002 | 324 | 0.240 |
Why?
|
| Bias | 4 | 2011 | 148 | 0.240 |
Why?
|
| Biometry | 4 | 2005 | 72 | 0.230 |
Why?
|
| Narcotic Antagonists | 1 | 2005 | 184 | 0.230 |
Why?
|
| Persian Gulf Syndrome | 4 | 2007 | 27 | 0.230 |
Why?
|
| Naltrexone | 1 | 2005 | 195 | 0.230 |
Why?
|
| Military Personnel | 7 | 2007 | 221 | 0.230 |
Why?
|
| Cocaine-Related Disorders | 2 | 2006 | 504 | 0.230 |
Why?
|
| Neuroprotective Agents | 1 | 2006 | 317 | 0.220 |
Why?
|
| Middle Aged | 35 | 2011 | 21147 | 0.210 |
Why?
|
| Motivation | 2 | 2005 | 561 | 0.200 |
Why?
|
| Adult | 40 | 2011 | 21403 | 0.200 |
Why?
|
| Diet | 1 | 2005 | 514 | 0.200 |
Why?
|
| Random Allocation | 5 | 2007 | 442 | 0.190 |
Why?
|
| Body Mass Index | 5 | 2008 | 867 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 3 | 2003 | 772 | 0.190 |
Why?
|
| Medical Futility | 2 | 2014 | 31 | 0.180 |
Why?
|
| Iowa | 13 | 2007 | 33 | 0.180 |
Why?
|
| Volcanic Eruptions | 1 | 1999 | 2 | 0.180 |
Why?
|
| Blood Pressure Determination | 2 | 2011 | 152 | 0.180 |
Why?
|
| Case-Control Studies | 9 | 2005 | 1553 | 0.170 |
Why?
|
| Anticoagulants | 7 | 2004 | 356 | 0.170 |
Why?
|
| Alcoholism | 3 | 2005 | 1109 | 0.170 |
Why?
|
| Dietary Fiber | 3 | 2008 | 37 | 0.160 |
Why?
|
| Monte Carlo Method | 4 | 2008 | 124 | 0.160 |
Why?
|
| United States | 18 | 2011 | 7367 | 0.160 |
Why?
|
| Circadian Rhythm | 1 | 1999 | 218 | 0.160 |
Why?
|
| Quality of Life | 5 | 2008 | 1515 | 0.160 |
Why?
|
| Health Status | 4 | 2007 | 429 | 0.150 |
Why?
|
| Aged | 23 | 2011 | 14862 | 0.150 |
Why?
|
| Smoking Cessation | 3 | 2007 | 1034 | 0.150 |
Why?
|
| Warfare | 4 | 2002 | 58 | 0.140 |
Why?
|
| Glycosaminoglycans | 2 | 1994 | 88 | 0.140 |
Why?
|
| Sample Size | 2 | 2008 | 79 | 0.140 |
Why?
|
| Students, Dental | 2 | 2007 | 49 | 0.140 |
Why?
|
| Fasting | 1 | 2016 | 75 | 0.140 |
Why?
|
| Cardiovascular Diseases | 3 | 2010 | 940 | 0.140 |
Why?
|
| Education, Dental | 2 | 2007 | 63 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2008 | 138 | 0.140 |
Why?
|
| Mental Disorders | 5 | 2007 | 659 | 0.140 |
Why?
|
| Thrombolytic Therapy | 4 | 2014 | 233 | 0.140 |
Why?
|
| Cross Infection | 5 | 2003 | 195 | 0.130 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 161 | 0.130 |
Why?
|
| Epidemiologic Methods | 3 | 2002 | 83 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 1997 | 191 | 0.130 |
Why?
|
| Analysis of Variance | 2 | 2016 | 1040 | 0.130 |
Why?
|
| Likelihood Functions | 3 | 2011 | 106 | 0.130 |
Why?
|
| Double-Blind Method | 6 | 2011 | 1738 | 0.120 |
Why?
|
| Perceptual Disorders | 2 | 2005 | 23 | 0.120 |
Why?
|
| Data Collection | 3 | 2003 | 420 | 0.120 |
Why?
|
| Blood Pressure | 3 | 2011 | 1451 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2008 | 3705 | 0.120 |
Why?
|
| Comorbidity | 5 | 2005 | 1426 | 0.110 |
Why?
|
| Hospitals, Veterans | 3 | 2003 | 147 | 0.110 |
Why?
|
| Prevalence | 8 | 2010 | 1619 | 0.110 |
Why?
|
| Cross-Sectional Studies | 6 | 2010 | 2279 | 0.110 |
Why?
|
| Risk | 4 | 1994 | 563 | 0.110 |
Why?
|
| Incidence | 5 | 2010 | 1603 | 0.100 |
Why?
|
| Observer Variation | 1 | 1993 | 330 | 0.100 |
Why?
|
| Severity of Illness Index | 6 | 2014 | 1851 | 0.100 |
Why?
|
| Clinical Competence | 2 | 2007 | 657 | 0.100 |
Why?
|
| Normal Distribution | 1 | 2011 | 46 | 0.100 |
Why?
|
| Risk Factors | 15 | 2007 | 5731 | 0.100 |
Why?
|
| Statistics, Nonparametric | 5 | 2008 | 306 | 0.100 |
Why?
|
| Retrospective Studies | 9 | 2007 | 7277 | 0.100 |
Why?
|
| Health Surveys | 3 | 2007 | 489 | 0.100 |
Why?
|
| Parkinson Disease | 3 | 2009 | 272 | 0.100 |
Why?
|
| Hemoglobin SC Disease | 1 | 2011 | 7 | 0.100 |
Why?
|
| Health Personnel | 2 | 2007 | 286 | 0.100 |
Why?
|
| Ambulatory Care | 4 | 2007 | 340 | 0.090 |
Why?
|
| Obesity | 3 | 2008 | 1076 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 1994 | 307 | 0.090 |
Why?
|
| Time Factors | 9 | 2007 | 4655 | 0.090 |
Why?
|
| Biomarkers | 5 | 2011 | 1593 | 0.090 |
Why?
|
| Antisickling Agents | 1 | 2011 | 20 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2006 | 186 | 0.090 |
Why?
|
| Hydroxyurea | 1 | 2011 | 57 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2014 | 951 | 0.090 |
Why?
|
| Odds Ratio | 6 | 2005 | 880 | 0.090 |
Why?
|
| Reproducibility of Results | 7 | 2002 | 2077 | 0.090 |
Why?
|
| Substance-Related Disorders | 3 | 2008 | 1242 | 0.090 |
Why?
|
| Neurology | 1 | 1989 | 43 | 0.080 |
Why?
|
| Operations Research | 1 | 1989 | 2 | 0.080 |
Why?
|
| Age Factors | 6 | 2007 | 1864 | 0.080 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2007 | 1506 | 0.080 |
Why?
|
| Evidence-Based Medicine | 2 | 2010 | 438 | 0.080 |
Why?
|
| Sampling Studies | 1 | 1989 | 80 | 0.080 |
Why?
|
| Acute Disease | 7 | 2005 | 658 | 0.080 |
Why?
|
| Mucin-1 | 1 | 2008 | 35 | 0.080 |
Why?
|
| Prognosis | 3 | 2010 | 2093 | 0.080 |
Why?
|
| Psyllium | 1 | 2008 | 3 | 0.080 |
Why?
|
| Ossification, Heterotopic | 1 | 2008 | 45 | 0.080 |
Why?
|
| Transplantation, Autologous | 1 | 2008 | 145 | 0.080 |
Why?
|
| Adolescent | 9 | 2011 | 8912 | 0.080 |
Why?
|
| Life Style | 1 | 2010 | 338 | 0.080 |
Why?
|
| Range of Motion, Articular | 1 | 2008 | 139 | 0.080 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2007 | 14 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2010 | 252 | 0.080 |
Why?
|
| Health Care Surveys | 3 | 2005 | 239 | 0.080 |
Why?
|
| Dietary Supplements | 2 | 2008 | 332 | 0.070 |
Why?
|
| Military Psychiatry | 1 | 2007 | 3 | 0.070 |
Why?
|
| Chi-Square Distribution | 3 | 2005 | 546 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 241 | 0.070 |
Why?
|
| Epidemiologic Studies | 1 | 2007 | 33 | 0.070 |
Why?
|
| Complement System Proteins | 1 | 2008 | 135 | 0.070 |
Why?
|
| Cohort Studies | 7 | 2010 | 2358 | 0.070 |
Why?
|
| Professional-Patient Relations | 1 | 2007 | 71 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2008 | 291 | 0.070 |
Why?
|
| Gadolinium | 1 | 2007 | 88 | 0.070 |
Why?
|
| Health Services | 1 | 2007 | 87 | 0.070 |
Why?
|
| Reoperation | 1 | 2008 | 467 | 0.070 |
Why?
|
| Functional Laterality | 2 | 2005 | 240 | 0.070 |
Why?
|
| Control Groups | 1 | 2006 | 10 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2005 | 1753 | 0.070 |
Why?
|
| Insurance, Health | 3 | 2007 | 201 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2007 | 121 | 0.070 |
Why?
|
| Cerebral Infarction | 3 | 2004 | 103 | 0.070 |
Why?
|
| Logistic Models | 4 | 2010 | 1420 | 0.070 |
Why?
|
| Skin Diseases | 1 | 2007 | 122 | 0.070 |
Why?
|
| Ocular Motility Disorders | 1 | 2005 | 15 | 0.070 |
Why?
|
| Registries | 3 | 2005 | 733 | 0.070 |
Why?
|
| Teaching | 1 | 2007 | 169 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 465 | 0.070 |
Why?
|
| Smoking Prevention | 2 | 2007 | 259 | 0.060 |
Why?
|
| Prisons | 1 | 2005 | 18 | 0.060 |
Why?
|
| Safety | 1 | 2006 | 145 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2007 | 1330 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 334 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2006 | 289 | 0.060 |
Why?
|
| Nutrition Policy | 1 | 2005 | 44 | 0.060 |
Why?
|
| Amlodipine | 1 | 2005 | 31 | 0.060 |
Why?
|
| Probability | 4 | 2011 | 245 | 0.060 |
Why?
|
| Anxiety Disorders | 2 | 2007 | 426 | 0.060 |
Why?
|
| Military Medicine | 1 | 2005 | 53 | 0.060 |
Why?
|
| Mental Health | 1 | 2007 | 278 | 0.060 |
Why?
|
| Leisure Activities | 1 | 2004 | 22 | 0.060 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2005 | 37 | 0.060 |
Why?
|
| Communication | 1 | 2007 | 329 | 0.060 |
Why?
|
| Predictive Value of Tests | 4 | 2004 | 1465 | 0.060 |
Why?
|
| Mouth Neoplasms | 1 | 2007 | 206 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 2005 | 138 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 365 | 0.060 |
Why?
|
| Esophagoscopy | 1 | 2004 | 72 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 212 | 0.060 |
Why?
|
| Pain | 1 | 2007 | 472 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2004 | 40 | 0.060 |
Why?
|
| Cocaine | 2 | 2006 | 555 | 0.060 |
Why?
|
| Membrane Fusion | 1 | 2003 | 7 | 0.060 |
Why?
|
| Giant Cells | 1 | 2003 | 14 | 0.060 |
Why?
|
| Herpesvirus 3, Human | 1 | 2003 | 12 | 0.060 |
Why?
|
| Computational Biology | 1 | 2005 | 190 | 0.060 |
Why?
|
| Virology | 1 | 2003 | 11 | 0.060 |
Why?
|
| Employment | 1 | 2004 | 154 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2003 | 83 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2001 | 373 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2003 | 98 | 0.050 |
Why?
|
| Curriculum | 1 | 2007 | 575 | 0.050 |
Why?
|
| Trauma Severity Indices | 2 | 1999 | 80 | 0.050 |
Why?
|
| Pre-Eclampsia | 1 | 2004 | 202 | 0.050 |
Why?
|
| Hospitalization | 4 | 2007 | 978 | 0.050 |
Why?
|
| Proportional Hazards Models | 4 | 2007 | 792 | 0.050 |
Why?
|
| American Hospital Association | 1 | 2002 | 6 | 0.050 |
Why?
|
| Patient Selection | 1 | 2006 | 592 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2003 | 163 | 0.050 |
Why?
|
| Follow-Up Studies | 5 | 2011 | 3259 | 0.050 |
Why?
|
| Ischemic Attack, Transient | 2 | 2004 | 167 | 0.050 |
Why?
|
| Benchmarking | 1 | 2002 | 91 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2005 | 301 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 450 | 0.050 |
Why?
|
| Preventive Health Services | 1 | 2002 | 86 | 0.050 |
Why?
|
| Gastroesophageal Reflux | 1 | 2004 | 318 | 0.050 |
Why?
|
| Universal Precautions | 1 | 2001 | 5 | 0.050 |
Why?
|
| Blood-Borne Pathogens | 1 | 2001 | 7 | 0.050 |
Why?
|
| Middle East | 4 | 2002 | 17 | 0.050 |
Why?
|
| Sex Distribution | 3 | 2007 | 274 | 0.050 |
Why?
|
| Radon | 1 | 2000 | 8 | 0.050 |
Why?
|
| Air Pollutants, Radioactive | 1 | 2000 | 11 | 0.050 |
Why?
|
| Multiple Chemical Sensitivity | 1 | 2000 | 5 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2002 | 307 | 0.050 |
Why?
|
| Aspirin | 1 | 2001 | 295 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2001 | 122 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2003 | 332 | 0.040 |
Why?
|
| Philippines | 1 | 1999 | 5 | 0.040 |
Why?
|
| Infection Control | 1 | 2001 | 101 | 0.040 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2000 | 79 | 0.040 |
Why?
|
| Environmental Exposure | 2 | 2000 | 269 | 0.040 |
Why?
|
| Cross-Cultural Comparison | 1 | 1999 | 68 | 0.040 |
Why?
|
| United Kingdom | 1 | 1999 | 152 | 0.040 |
Why?
|
| Candidiasis | 2 | 1989 | 39 | 0.040 |
Why?
|
| Carotid Artery, Internal | 1 | 1999 | 85 | 0.040 |
Why?
|
| Exercise | 1 | 2004 | 658 | 0.040 |
Why?
|
| Aged, 80 and over | 8 | 2004 | 4848 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 442 | 0.040 |
Why?
|
| Health Services Research | 1 | 1999 | 209 | 0.040 |
Why?
|
| Forecasting | 1 | 1999 | 277 | 0.040 |
Why?
|
| Surveys and Questionnaires | 5 | 2005 | 2800 | 0.040 |
Why?
|
| Carotid Stenosis | 1 | 1999 | 163 | 0.040 |
Why?
|
| Smoking | 5 | 2003 | 1452 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2002 | 445 | 0.040 |
Why?
|
| Fungemia | 1 | 1997 | 13 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1999 | 782 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2005 | 714 | 0.040 |
Why?
|
| Multivariate Analysis | 4 | 2005 | 1046 | 0.040 |
Why?
|
| Depression | 2 | 2003 | 943 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2000 | 334 | 0.040 |
Why?
|
| Databases, Factual | 1 | 1999 | 622 | 0.030 |
Why?
|
| Linear Models | 2 | 2002 | 521 | 0.030 |
Why?
|
| Patient Dropouts | 2 | 2008 | 98 | 0.030 |
Why?
|
| Least-Squares Analysis | 2 | 1994 | 35 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 1999 | 621 | 0.030 |
Why?
|
| Blood Glucose | 1 | 1999 | 631 | 0.030 |
Why?
|
| Uveal Neoplasms | 1 | 1995 | 16 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2000 | 1173 | 0.030 |
Why?
|
| Ciliary Body | 1 | 1995 | 52 | 0.030 |
Why?
|
| Bacteremia | 1 | 1997 | 155 | 0.030 |
Why?
|
| Brain | 1 | 2005 | 2176 | 0.030 |
Why?
|
| Blood Urea Nitrogen | 2 | 2010 | 65 | 0.030 |
Why?
|
| Confidence Intervals | 3 | 2004 | 242 | 0.030 |
Why?
|
| Certification | 1 | 1994 | 66 | 0.030 |
Why?
|
| Age Distribution | 2 | 2005 | 320 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 1994 | 136 | 0.030 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 1993 | 45 | 0.030 |
Why?
|
| Women's Health | 2 | 2007 | 148 | 0.030 |
Why?
|
| Embolism | 1 | 1993 | 45 | 0.030 |
Why?
|
| Research | 1 | 1994 | 214 | 0.030 |
Why?
|
| Arteriosclerosis | 1 | 1993 | 137 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2005 | 392 | 0.030 |
Why?
|
| Prenatal Care | 1 | 1993 | 117 | 0.030 |
Why?
|
| Disease Progression | 2 | 2007 | 1038 | 0.030 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1993 | 134 | 0.030 |
Why?
|
| Disease Management | 1 | 2014 | 248 | 0.030 |
Why?
|
| Heparinoids | 1 | 1992 | 3 | 0.030 |
Why?
|
| Recurrence | 2 | 2004 | 948 | 0.020 |
Why?
|
| Melanoma | 1 | 1995 | 335 | 0.020 |
Why?
|
| Patient Compliance | 2 | 2005 | 402 | 0.020 |
Why?
|
| Drug Combinations | 2 | 2004 | 304 | 0.020 |
Why?
|
| Erythrocyte Indices | 1 | 2011 | 9 | 0.020 |
Why?
|
| Fetal Hemoglobin | 1 | 2011 | 10 | 0.020 |
Why?
|
| Algorithms | 2 | 2008 | 1196 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2011 | 137 | 0.020 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2011 | 89 | 0.020 |
Why?
|
| Decision Making | 1 | 2014 | 410 | 0.020 |
Why?
|
| Models, Theoretical | 2 | 2005 | 384 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 177 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 1999 | 1536 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 324 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 219 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 279 | 0.020 |
Why?
|
| Glasgow Coma Scale | 2 | 1999 | 65 | 0.020 |
Why?
|
| Water Supply | 1 | 1989 | 54 | 0.020 |
Why?
|
| Southeastern United States | 1 | 2010 | 281 | 0.020 |
Why?
|
| CD55 Antigens | 1 | 2008 | 13 | 0.020 |
Why?
|
| Membrane Cofactor Protein | 1 | 2008 | 7 | 0.020 |
Why?
|
| Heparin | 1 | 1989 | 205 | 0.020 |
Why?
|
| Chlorine | 1 | 1989 | 76 | 0.020 |
Why?
|
| CD59 Antigens | 1 | 2008 | 30 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2010 | 195 | 0.020 |
Why?
|
| Tumor Escape | 1 | 2008 | 37 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2005 | 2007 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2008 | 87 | 0.020 |
Why?
|
| Diagnosis, Oral | 1 | 2007 | 14 | 0.020 |
Why?
|
| Community Health Planning | 1 | 2007 | 19 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 27 | 0.020 |
Why?
|
| Sex Factors | 3 | 2003 | 1266 | 0.020 |
Why?
|
| Tobacco Use Cessation | 1 | 2007 | 44 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 507 | 0.020 |
Why?
|
| Immunoassay | 1 | 2007 | 64 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2007 | 117 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 710 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2007 | 99 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2011 | 3187 | 0.020 |
Why?
|
| Models, Educational | 1 | 2007 | 67 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 260 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2008 | 330 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2007 | 328 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 208 | 0.020 |
Why?
|
| Problem-Based Learning | 1 | 2007 | 72 | 0.020 |
Why?
|
| Gene Expression | 1 | 2008 | 770 | 0.020 |
Why?
|
| Orientation | 1 | 2005 | 31 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1174 | 0.020 |
Why?
|
| Space Perception | 1 | 2005 | 44 | 0.020 |
Why?
|
| Overweight | 1 | 2007 | 186 | 0.020 |
Why?
|
| Vehicle Emissions | 1 | 1985 | 11 | 0.020 |
Why?
|
| Fibrosis | 1 | 2007 | 371 | 0.020 |
Why?
|
| Ubiquinone | 1 | 2005 | 14 | 0.020 |
Why?
|
| Parietal Lobe | 1 | 2005 | 59 | 0.020 |
Why?
|
| Oculomotor Muscles | 1 | 2005 | 54 | 0.020 |
Why?
|
| Length of Stay | 1 | 1988 | 780 | 0.020 |
Why?
|
| Counseling | 1 | 2007 | 280 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1985 | 68 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 517 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2007 | 225 | 0.020 |
Why?
|
| Connecticut | 1 | 2004 | 13 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2007 | 254 | 0.020 |
Why?
|
| Time and Motion Studies | 1 | 2004 | 16 | 0.020 |
Why?
|
| Hemodilution | 2 | 1994 | 9 | 0.020 |
Why?
|
| Substance Abuse Detection | 1 | 2005 | 66 | 0.020 |
Why?
|
| Telephone | 1 | 2005 | 160 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2005 | 114 | 0.020 |
Why?
|
| Psychometrics | 1 | 2007 | 514 | 0.020 |
Why?
|
| Urban Health | 1 | 2004 | 49 | 0.010 |
Why?
|
| Basal Ganglia | 1 | 2004 | 45 | 0.010 |
Why?
|
| Dominance, Cerebral | 1 | 2004 | 65 | 0.010 |
Why?
|
| Frontal Lobe | 1 | 2005 | 156 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1664 | 0.010 |
Why?
|
| Pregnancy | 2 | 2004 | 2334 | 0.010 |
Why?
|
| Contrast Media | 1 | 2007 | 595 | 0.010 |
Why?
|
| Thalamus | 1 | 2004 | 82 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2006 | 275 | 0.010 |
Why?
|
| Socioeconomic Factors | 2 | 2000 | 955 | 0.010 |
Why?
|
| South Dakota | 1 | 2003 | 1 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2003 | 4 | 0.010 |
Why?
|
| Attention | 1 | 2005 | 225 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2005 | 324 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 2003 | 43 | 0.010 |
Why?
|
| Health Planning Guidelines | 1 | 2003 | 23 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2003 | 226 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2003 | 237 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2004 | 222 | 0.010 |
Why?
|
| Child | 2 | 2011 | 6405 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 179 | 0.010 |
Why?
|
| Bacteria | 1 | 2003 | 193 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2005 | 2324 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2005 | 400 | 0.010 |
Why?
|
| Inflammation | 1 | 2008 | 1030 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 2 | 2003 | 1026 | 0.010 |
Why?
|
| Hospitals | 1 | 2003 | 265 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 415 | 0.010 |
Why?
|
| Virginia | 1 | 2001 | 45 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 767 | 0.010 |
Why?
|
| Mortality | 1 | 1982 | 163 | 0.010 |
Why?
|
| Inservice Training | 1 | 2001 | 68 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 567 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2001 | 123 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2000 | 84 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2000 | 201 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 1999 | 25 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 240 | 0.010 |
Why?
|
| Medical Record Linkage | 1 | 1999 | 42 | 0.010 |
Why?
|
| SEER Program | 1 | 1999 | 153 | 0.010 |
Why?
|
| Placebos | 1 | 1999 | 195 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1999 | 109 | 0.010 |
Why?
|
| Survival Rate | 1 | 2001 | 1056 | 0.010 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 1999 | 41 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 2223 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2000 | 285 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1983 | 629 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2006 | 1615 | 0.010 |
Why?
|
| Affective Symptoms | 1 | 1977 | 50 | 0.010 |
Why?
|
| Choroid Neoplasms | 1 | 1995 | 20 | 0.010 |
Why?
|
| Microcirculation | 1 | 1995 | 77 | 0.010 |
Why?
|
| Obstetric Labor, Premature | 1 | 1993 | 76 | 0.010 |
Why?
|
| Prothrombin | 1 | 1992 | 12 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1992 | 47 | 0.010 |
Why?
|
| Factor Xa Inhibitors | 1 | 1992 | 43 | 0.010 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 1989 | 9 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1992 | 328 | 0.010 |
Why?
|
| Classification | 1 | 1989 | 8 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 1989 | 190 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1992 | 1342 | 0.000 |
Why?
|
| Chemical Industry | 1 | 1985 | 5 | 0.000 |
Why?
|
| Occupations | 1 | 1985 | 27 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1988 | 2455 | 0.000 |
Why?
|
| Infant | 1 | 1988 | 2891 | 0.000 |
Why?
|
| Antisocial Personality Disorder | 1 | 1977 | 30 | 0.000 |
Why?
|
| Genes | 1 | 1977 | 86 | 0.000 |
Why?
|